For patients with relapsed or refractory DLBCL
Also pursuing a second-line treatment indication

Starting December 1, South Korea's first domestically developed chimeric antigen receptor T-cell (CAR-T) therapy, Rimcato, will be covered by national health insurance.


Curocell announced on November 20 that the reimbursement ceiling per dose of Rimcato has been set at 280,016,050 won.


A view of Curocell's Daejeon headquarters (research institute) and GMP plant. Curocell

A view of Curocell's Daejeon headquarters (research institute) and GMP plant. Curocell

View original image

With the coverage taking effect, adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will be able to receive Rimcato treatment with national health insurance benefits.


Curocell is also pursuing an expansion of Rimcato's indications. Last month, it applied for approval of an amendment to its investigational new drug (IND) plan for a Phase 3 clinical trial to secure a second-line treatment indication for relapsed or refractory diffuse large B-cell lymphoma. It aims to begin the Phase 3 trial in the first half of next year.



"With Rimcato now covered by national health insurance, we can offer a real treatment opportunity to patients who had to hesitate because of the cost," Curocell CEO Kim Geonsu said. "We will work closely with medical institutions and ensure the supply system runs smoothly so patients can receive treatment promptly and reliably."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing